Oncology and Hematology

Episodes 1-16 of 27

• 

  CME/CE Meeting

  Mastering HER2 in GI Malignancies: Incorporating a Multidisciplinary Approach to Current and Emerging Management

  January 19, 2024

  06:00 PM - 08:00 PM PST

  • 

    

    James J. Harding, MD

    Peer

  • 

    

    Kanwal Raghav, MD

    Peer

  1.50 credits Learn more

• 

  MinuteCE®

  Sickle Cell Disease Across the Life Span: What Your Patients Want You to Know

  1.00 credit 10 episodes

  • 

    

    Biree Andemariam, MD

    Peer

  • 

    

    Caroline Freiermuth, MD

    Peer

  1.00 credit 10 episodes

• 

  RestartResume

  Keeping Pace in Hematologic Malignancies: 2023
  Contextualizing the Evidence: Newly Diagnosed AML in Difficult-to-Treat Subtypes

  RestartResume

  Keeping Pace in Hematologic Malignancies: 2023
  Contextualizing the Evidence: Newly Diagnosed AML in Difficult-to-Treat Subtypes

  CME/CE

  Keeping Pace in Hematologic Malignancies: 2023
  Contextualizing the Evidence: Newly Diagnosed AML in Difficult-to-Treat Subtypes

  0.50 credits

  • 

    

    Harry Paul Erba, MD, PhD

    Peer

  • 

    

    Courtney DiNardo, MD

    Peer

  0.50 credits

• 

  RestartResume

  Delivering Change: Mechanisms to Address Racial Healthcare Disparities in Multiple Myeloma

  RestartResume

  Delivering Change: Mechanisms to Address Racial Healthcare Disparities in Multiple Myeloma

  CME/CE

  Delivering Change: Mechanisms to Address Racial Healthcare Disparities in Multiple Myeloma

  0.25 credits

  • 

    

    Joseph Mikhael, MD

    Peer

  • 

    

    Monique Hartley-Brown, MD

    Peer

  • 

    

    Brandon Blue, MD

    Peer

  0.25 credits

• 

  RestartResume

  In the Medical Spotlight: Antibody-Drug Conjugates in Advanced HER2-Positive Gastric/Gastroesophageal Junction Cancer

  RestartResume

  In the Medical Spotlight: Antibody-Drug Conjugates in Advanced HER2-Positive Gastric/Gastroesophageal Junction Cancer

  CME/CE

  In the Medical Spotlight: Antibody-Drug Conjugates in Advanced HER2-Positive Gastric/Gastroesophageal Junction Cancer

  0.25 credits

  • 

    

    John L. Marshall, MD

    Peer

  0.25 credits

• 

  RestartResume

  Individualizing Frontline Treatment

  RestartResume

  Individualizing Frontline Treatment

  MinuteCE®

  Individualizing Frontline Treatment

  1.00 program credit

  • 

    

    Alex Herrera, MD

    Peer

  • 

    

    Alison J. Moskowitz, MD

    Peer

  1.00 program credit

• 

  RestartResume

  Patient Selection for ADCs in First-Line DLBCL

  RestartResume

  Patient Selection for ADCs in First-Line DLBCL

  MinuteCE®

  Patient Selection for ADCs in First-Line DLBCL

  1.00 program credit

  • 

    

    John P. Leonard, MD

    Peer

  • 

    

    Sarah Rutherford, MD

    Peer

  1.00 program credit

• 

  RestartResume

  Clinical Implications of Bispecific Antibodies and Antibody-Drug Conjugates in FL

  RestartResume

  Clinical Implications of Bispecific Antibodies and Antibody-Drug Conjugates in FL

  MinuteCE®

  Clinical Implications of Bispecific Antibodies and Antibody-Drug Conjugates in FL

  1.00 program credit

  • 

    

    Kami Maddocks, MD

    Peer

  • 

    

    Matthew J. Matasar, MD

    Peer

  1.00 program credit

• 

  RestartResume

  Bispecific Antibodies in FL

  RestartResume

  Bispecific Antibodies in FL

  MinuteCE®

  Bispecific Antibodies in FL

  1.00 program credit

  • 

    

    Kami Maddocks, MD

    Peer

  • 

    

    Matthew J. Matasar, MD

    Peer

  1.00 program credit

• 

  RestartResume

  Application of Data from the ECHELON-1 Trial

  RestartResume

  Application of Data from the ECHELON-1 Trial

  MinuteCE®

  Application of Data from the ECHELON-1 Trial

  1.00 program credit

  • 

    

    Alison J. Moskowitz, MD

    Peer

  • 

    

    Alex Herrera, MD

    Peer

  1.00 program credit

• 

  RestartResume

  First-Line Treatment of Adults with Classical Hodgkin Lymphoma 

  RestartResume

  First-Line Treatment of Adults with Classical Hodgkin Lymphoma 

  MinuteCE®

  First-Line Treatment of Adults with Classical Hodgkin Lymphoma 

  1.00 program credit

  • 

    

    Alex Herrera, MD

    Peer

  • 

    

    Alison J. Moskowitz, MD

    Peer

  1.00 program credit

• 

  RestartResume

  NCCN Guideline Updates in DLBCL

  RestartResume

  NCCN Guideline Updates in DLBCL

  MinuteCE®

  NCCN Guideline Updates in DLBCL

  1.00 program credit

  • 

    

    John P. Leonard, MD

    Peer

  • 

    

    Sarah Rutherford, MD

    Peer

  1.00 program credit

• 

  RestartResume

  Antibody-Drug Conjugates in FL

  RestartResume

  Antibody-Drug Conjugates in FL

  MinuteCE®

  Antibody-Drug Conjugates in FL

  1.00 program credit

  • 

    

    Matthew J. Matasar, MD

    Peer

  • 

    

    Kami Maddocks, MD

    Peer

  1.00 program credit

• 

  MinuteCE®

  Contextualizing the Evidence in Lymphomas: ADCs and Bispecific Antibodies in HL, FL, and DLBCL

  1.00 credit 9 episodes

  • 

    

    John P. Leonard, MD

    Peer

  • 

    

    Matthew J. Matasar, MD

    Peer

  • 

    

    Alex Herrera, MD

    Peer

  • 

    

    Kami Maddocks, MD

    Peer

  • 

    

    Alison J. Moskowitz, MD

    Peer

  • 

    

    Sarah Rutherford, MD

    Peer

  1.00 credit 9 episodes

• 

  RestartResume

  Late-Stage Bispecifics and ADCs in DLBCL

  RestartResume

  Late-Stage Bispecifics and ADCs in DLBCL

  MinuteCE®

  Late-Stage Bispecifics and ADCs in DLBCL

  1.00 program credit

  • 

    

    Sarah Rutherford, MD

    Peer

  • 

    

    John P. Leonard, MD

    Peer

  1.00 program credit

• 

  RestartResume

  Preventing Disease Recurrence with Adjuvant Therapy in Stage IIB/IIC Melanoma 

  RestartResume

  Preventing Disease Recurrence with Adjuvant Therapy in Stage IIB/IIC Melanoma 

  CME/CE

  Preventing Disease Recurrence with Adjuvant Therapy in Stage IIB/IIC Melanoma 

  0.25 credits

  • 

    

    Jason J. Luke, MD, FACP

    Peer

  • 

    

    Tara C. Mitchell, MD

    Peer

  0.25 credits

• Prev
• 1
• 2
• Next